{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-24-000058","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.407551+00:00","generated_at":"2026-06-02T12:44:59.682144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Maravai Q1 revenue down 19% to $64.2M; net loss widens to $22.7M; FY guide reaffirmed","bullets":["Quarterly revenue $64.2M, down 19% YoY; Nucleic Acid Production fell 25% to $46.0M.","Net loss of $22.7M vs $1.3M loss in Q1 2023; Adjusted EBITDA $7.8M vs $23.8M.","Biologics Safety Testing revenue up 3.4% to $18.2M.","Reaffirmed FY2024 revenue guidance $265M–$285M.","Entered non-exclusive CleanCap license agreement with Lonza for mRNA services."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-24-000058","json":"https://secwatch.observer/filing/0001823239-24-000058.json","markdown":"https://secwatch.observer/filing/0001823239-24-000058.md","text":"https://secwatch.observer/filing/0001823239-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/0001823239-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/mrvi-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:44:59.682144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad084b63d3d5443aacea4eeaf36bff9790dfc4f5","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. updated its first quarter ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"On May 8, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000058/0001823239-24-000058-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}